Last edition
News about "IgA nephropathy "
Chugai Files Regulatory Application in Japan for IgA Nephropathy Drug Sparsentan
Chugai Pharmaceutical has applied for regulatory approval in Japan for sparsentan, a dual-action oral therapy for IgA nephropathy. Clinical studies showed significant reductions in proteinuria and potential benefits in preserving kidney function, offering hope for patients with limited treatment options.
IgA Nephropathy | 20/06/2026 | By News Bureau
AstraZeneca's Ultomiris Granted FDA Priority Review for Rare Kidney Disease IgAN
The US FDA has granted Priority Review to AstraZeneca’s supplemental application for Ultomiris in immunoglobulin A nephropathy, bringing the therapy closer to becoming the first C5 complement inhibitor approved for the rare kidney disease.
IgA Nephropathy | 16/06/2026 | By News Bureau
Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy
Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.
IgA Nephropathy | 29/05/2026 | By News Bureau | 120
Otsuka receives FDA accelerated approval for Voyxact in adults with IgA nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the US FDA has granted accelerated approval for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
IgA Nephropathy | 27/11/2025 | By Darshana | 435
Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia
Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.
IgA Nephropathy | 24/10/2025 | By Dineshwori | 559
Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan
In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
IgA Nephropathy | 01/02/2025 | By Abha | 757
Novartis Presents Interim Analysis of atrasentan Phase III Data
Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).
IgA Nephropathy | 28/05/2024 | By Aishwarya | 809
Vertex Signs Agreement to Acquire Alpine Immune Sciences
Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
IgA Nephropathy | 11/04/2024 | By Aishwarya | 893
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy